This brief will present a snapshot of hepatitis B and C testing in the European Union/European Economic Area (EU/EEA), discussing progress made towards the European action plan 2020 testing target, focussing on key populations and settings for testing, barriers to testing, and testing policies.
This report presents the results of a systematic literature review investigating the impact of novel strategies and approaches (using existing and/or novel testing technologies) on access to testing, testing coverage, and linkage to care of key populations at-risk for sexually transmitted infections (STIs).
This operational guidance document provides practical recommendations and key considerations to inform the development and
implementation of PrEP programmes at national and sub-national levels throughout the EU/EEA.
This report is the latest in a series published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe that has been summarizing data on HIV and AIDS in the WHO European Region and in the European Union and European Economic Area (EU/EEA) since 2007.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
For 2018, 30 EU/EEA Member States reported 24 588 cases of hepatitis B virus (HBV) infection. When the five countries that only reported acute cases are excluded, the number of cases is 24 034, which corresponds to a crude rate of 6.0 cases per 100 000 population.